Application of tetrahydrocannabivarinic in prevention and/or treatment of pulmonary arterial hypertension

A technology of tetrahydrocannabinol and pulmonary arterial hypertension, applied in the field of medicine, can solve problems such as the lack of a cure for pulmonary arterial hypertension, the uncurable mortality rate of pulmonary arterial hypertension, etc.

Active Publication Date: 2021-07-16
HANYI BIO TECH CO LTD
View PDF4 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] Although these drugs can alleviate the symptoms of PAH to a certain extent, pulmonary hypertension is still an incurable disease with a high mortality rate. The median survival time of patients under treatment is only 2.7 years. Therefore, it is particularly urgent to find new specific therapeutic drugs

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of tetrahydrocannabivarinic in prevention and/or treatment of pulmonary arterial hypertension
  • Application of tetrahydrocannabivarinic in prevention and/or treatment of pulmonary arterial hypertension
  • Application of tetrahydrocannabivarinic in prevention and/or treatment of pulmonary arterial hypertension

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0089] 1. Experimental animals, reagents and instruments

[0090] (1) Experimental animals

[0091] 4-6 weeks old mice, healthy and active, with shiny coat color, weighing (25.15±2.15) g, C57BL / 6 (Experimental Animal Center of Military Science and Medical College, SPF grade). Group the experimental animals as follows:

[0092] Group 1 (normoxic wild type, as a control group): under normoxia, 10 female mice and 10 male mice;

[0093] Group 2 (anoxic wild type, as a control group): under hypoxic conditions, 10 female mice and 10 male mice;

[0094] Group 3 (THCV administration group, 0.2 mg / kg body weight): intragastric administration under hypoxic conditions, 10 female mice and 10 male mice;

[0095] Group 4 (THCV administration group, 0.4mg / kg body weight): intragastric administration under hypoxic conditions, 10 female mice and 10 male mice;

[0096] Group 5 (THCV administration group, 0.8 mg / kg body weight): intragastric administration under hypoxic conditions, 10 female...

Embodiment 2

[0158] With reference to the relevant parameters of Example 1, the experimental mice were taken and grouped as follows:

[0159] Group 1 (combined administration group THCV 0.4mg / kg body weight + CBD 10mg / kg body weight): intragastric administration under hypoxic conditions, 10 female mice and 10 male mice;

[0160] Group 2 (combined administration group THCV 0.4mg / kg body weight + CBDV 2mg / kg body weight): intragastric administration under hypoxic conditions, 10 female mice and 10 male mice;

[0161] Group 3 (combined administration group THCV 0.4 mg / kg body weight + CBG 0.5 mg / kg body weight): intragastric administration under hypoxic conditions, 10 female rats and 10 male rats.

[0162] Group 4 (combined administration group THCV 0.4 mg / kg body weight + CBD 10 mg / kg body weight + CBDV 2 mg / kg body weight): intragastric administration under hypoxic conditions, 10 female mice and 10 male mice;

[0163] Group 5 (combined administration group THCV 0.4mg / kg body weight+CBD 10mg...

Embodiment 3

[0175] Take industrial hemp flowers and leaves and grind them, pass through No. 1 sieve, bake at 100°C for 200 minutes, take a certain amount of roasted cannabis flowers and leaves medicinal materials, add 70% ethanol according to the material-to-liquid ratio of 1:8 (w / v), and stir at room temperature Extract twice, 1 hour each time, filter, combine the extracts, centrifugal filter, concentrate the centrifugal filtrate under reduced pressure (65°C, -0.08~-0.09Mpa) until it has no alcohol smell and the density is 1.070 (60°C), add Purify the water until the weight of the solution is 8 times the weight of the medicinal materials, and stir evenly to obtain the sample solution.

[0176] Measure the sample solution, purify it through a treated macroporous resin column (diameter-to-height ratio: 1:5) at a flow rate of 4BV / h, let it stand for 60 minutes after loading, and then use purified water at a flow rate of 9BV / h , 50% ethanol, 80% ethanol elution, use molish reaction to determ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses application of tetrahydrocannabivarinic in prevention and/or treatment of pulmonary arterial hypertension, and particularly relates to application of a composition containing tetrahydrocannabivarinic in prevention and/or treatment of pulmonary arterial hypertension and complications thereof. The tetrahydrocannabivarinic, especially a composition containing the tetrahydrocannabivarinic and other cannabinoid Cannabinoids, can significantly reduce right ventricular systolic pressure and right ventricular hypertrophy index of pulmonary arterial hypertension model mice, improve pulmonary edema and hepatic edema, can improve pulmonary arterial hypertension diseases, and especially, the combined administration can enhance the improvement effect on hepatic edema, and has important value for the development of drugs for treating pulmonary arterial hypertension.

Description

technical field [0001] The present invention relates to the field of medical technology, in particular to the application of tetrahydrocannabinol (THCV) in the prevention and / or treatment of pulmonary hypertension, in particular to the application of a composition containing THCV in pulmonary hypertension and its complications. prophylactic and / or therapeutic applications. Background technique [0002] Pulmonary arterial hypertension (PAH) refers to a hemodynamic and pathophysiological state in which pulmonary artery pressure rises above a certain threshold. Mean pulmonary artery pressure ≥ 25mmHg. Pulmonary hypertension mainly involves the pulmonary artery and right heart, manifested as right ventricular hypertrophy and right atrium dilation. The main pulmonary artery is dilated and the surrounding pulmonary arterioles are sparse. Pulmonary arteriole endothelial cells and smooth muscle cells hyperplasia and hypertrophy, intima fibrosis and thickening, medial hypertrophy,...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/05A61K31/352A61P11/00A61P9/12
CPCA61K31/05A61K31/352A61P11/00A61P9/12A61K2300/00A61P1/16A61K31/353
Inventor 谭昕王曙宾张可孙武兴
Owner HANYI BIO TECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap